{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:24:39Z","timestamp":1788607479958,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,10,9]],"date-time":"2017-10-09T00:00:00Z","timestamp":1507507200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s11883-017-0682-x","type":"journal-article","created":{"date-parts":[[2017,10,8]],"date-time":"2017-10-08T20:13:29Z","timestamp":1507493609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical Guidance for Managing Statin and Antimicrobial Drug-Drug Interactions"],"prefix":"10.1007","volume":"19","author":[{"given":"Leigh Anne","family":"Hylton Gravatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel W.","family":"Flurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estela","family":"Lajthia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave L.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,9]]},"reference":[{"issue":"21","key":"682_CR1","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","volume":"134","author":"BS Wiggins","year":"2016","unstructured":"\u2022\u2022 Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468\u201395. A recent scientific statement from AHA that provides an extensive overview of drug-drug interactions with statins.","journal-title":"Circulation"},{"issue":"10","key":"682_CR2","first-page":"1266","volume":"161","author":"LE Shapiro","year":"1999","unstructured":"Shapiro LE, Shear NH. Drug-drug interactions: how scared should we be? Cana Med Assoc J. 1999;161(10):1266\u20137.","journal-title":"Cana Med Assoc J"},{"key":"682_CR3","first-page":"1","volume":"2013","author":"NJ Stone","year":"2013","unstructured":"Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Lloyd-Jones DM, et al. ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2013;2013:1\u201385.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"682_CR4","first-page":"e1","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics\u20142017 update: a report from the American Heart Association. Circulation. 2017;135(24):e1\u2013e458.","journal-title":"Circulation"},{"issue":"20","key":"682_CR5","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","volume":"67","author":"PD Thompson","year":"2016","unstructured":"\u2022\u2022 Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395\u2013410. A review comprehensive review of factors that contribute to increasing the risk of statin-associated side effects, including drug-drug interactions","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"682_CR6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1345\/aph.1A289","volume":"36","author":"MA Omar","year":"2002","unstructured":"Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36(2):288\u201395.","journal-title":"Ann Pharmacother"},{"issue":"9","key":"682_CR7","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/cid\/civ076","volume":"60","author":"LA Hicks","year":"2015","unstructured":"Hicks LA, Bartoces MG, Roberts RM, Suda KJ, Hunkler RJ, Taylor TH, et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis. 2015;60(9):1308\u201316.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"682_CR8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jacl.2008.10.007","volume":"2","author":"EE Ming","year":"2008","unstructured":"Ming EE, Davidson MH, Gandhi SK, Marotti M, Miles CG, Ke X, et al. Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol. 2008;2(6):453\u201363.","journal-title":"J Clin Lipidol"},{"issue":"Suppl A","key":"682_CR9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/jac\/16.suppl_A.181","volume":"16","author":"D Pessayre","year":"1985","unstructured":"Pessayre D, Larrey D, Funck-Brentano C, Benhamou JP. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother. 1985;16(Suppl A):181\u201394.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"682_CR10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00002018-199513020-00005","volume":"13","author":"NA Rosensteil von","year":"1995","unstructured":"von Rosensteil NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf. 1995 [cited 2017 Jun 9];13(2):105\u201322.","journal-title":"Drug Saf"},{"issue":"1","key":"682_CR11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","volume":"75","author":"C Marzolini","year":"2004","unstructured":"Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75(1):13\u201333.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"682_CR12","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1124\/dmd.106.014407","volume":"35","author":"A Seithel","year":"2007","unstructured":"Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos. 2007;35(5):779\u201386.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"682_CR13","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","volume":"94","author":"TA Jacobson","year":"2004","unstructured":"Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94(9):1140\u20136.","journal-title":"Am J Cardiol"},{"issue":"2","key":"682_CR14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0009-9236(98)90151-5","volume":"64","author":"T Kantola","year":"1998","unstructured":"Kantola T, Kivist\u00f6 KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 1998;64(2):177\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"682_CR15","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/009127009903900510","volume":"39","author":"PH Siedlik","year":"1999","unstructured":"Siedlik PH, Olson SC, Yang BB, Stern RH. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol. 1999;39(5):501\u20134.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"682_CR16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00228-003-0573-7","volume":"59","author":"KJ Cooper","year":"2003","unstructured":"Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 2003;59(1):51\u20136.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"682_CR17","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1185\/03007995.2011.589433","volume":"27","author":"A Corsini","year":"2011","unstructured":"Corsini A, Ceska R. Drug\u2013drug interactions with statins: will pitavastatin overcome the statins\u2019 Achilles\u2019 heel? Curr Med Res Opin. 2011;27(8):1551\u201362.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"682_CR18","doi-asserted-by":"crossref","first-page":"869","DOI":"10.7326\/0003-4819-158-12-201306180-00004","volume":"158","author":"AM Patel","year":"2013","unstructured":"\u2022\u2022 Patel AM, Shariff S, Bailey DG, Juurlink DN, Gandhi S, Mamdani M, et al. Statin toxicity from macrolide antibiotic coprescription. Ann Intern Med. 2013;158(12):869. A recent study demonstrating an increased risk of rhabdomyolysis, acute kidney injury, and all-cause mortality in older adult statin users prescribed a macrolide antibiotic.","journal-title":"Ann Intern Med"},{"issue":"3","key":"682_CR19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1503\/cmaj.140950","volume":"187","author":"DQ Li","year":"2015","unstructured":"Li DQ, Kim R, McArthur E, Fleet JL, Bailey DG, Juurlink D, et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Can Med Assoc J. 2015;187(3):174\u201380.","journal-title":"Can Med Assoc J"},{"key":"682_CR20","unstructured":"U.S. Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs [Internet]. Available at: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm293101.htm . Accessed 15 June 2017."},{"key":"682_CR21","unstructured":"Erythromycin [package insert]. Atlanta: Arbor Pharmaceuticals, 2012."},{"key":"682_CR22","unstructured":"Biaxin [package insert]. North Chicago: Abbott Laboratories."},{"key":"682_CR23","unstructured":"Zithromax [package insert]. New York: Pfizer Inc., 2013."},{"key":"682_CR24","unstructured":"Lescol [package insert]. East Hanover: Novartis; 2012."},{"key":"682_CR25","unstructured":"Diflucan [package insert]. New York: Pfizer 2014."},{"key":"682_CR26","unstructured":"Sporanox [package insert]. Titusville: Janssen Pharmaceuticals; 2010."},{"key":"682_CR27","unstructured":"Cresemba [package insert]. Northbrook: Astella Pharmaceuticals; 2015."},{"key":"682_CR28","unstructured":"Nizoral [package insert]. Titusville: Janssen Pharmaceuticals; 2013."},{"issue":"1","key":"682_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425255.2012.639360","volume":"8","author":"G Krishna","year":"2012","unstructured":"Krishna G, Ma L, Prasad P, Moton A, Martinho M, O\u2019Mara E. Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers. Expert Opin Drug Metab Toxicol. 2012;8(1):1\u201310.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9","key":"682_CR30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archinte.162.9.985","volume":"162","author":"CK Finch","year":"2002","unstructured":"Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions. Arch Intern Med. 2002;162(9):985.","journal-title":"Arch Intern Med"},{"issue":"7","key":"682_CR31","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0149-2918(08)80052-5","volume":"30","author":"W Zhang","year":"2008","unstructured":"Zhang W, Deng S, Chen X-P, Zhou G, Xie H-T, He F-Y, et al. Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008;30(7):1283\u20139.","journal-title":"Clin Ther"},{"issue":"11","key":"682_CR32","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00228-013-1554-0","volume":"69","author":"Y Chen","year":"2013","unstructured":"Chen Y, Zhang W, Huang W, Tan Z, Wang Y, Huang X, et al. Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers. Eur J Clin Pharmacol. 2013;69(11):1933\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"682_CR33","unstructured":"Lipitor [package insert]. New York: Pfizer Inc., 2009."},{"key":"682_CR34","unstructured":"Zocor [package inert]. Whitehouse Station: Merck & Co., Inc., 2010. Cubicin [package insert]."},{"key":"682_CR35","first-page":"761393","volume":"2015","author":"N Schryver De","year":"2015","unstructured":"De Schryver N, Wittebole X, Van den Bergh P, Haufroid V, Goffin E, Hantson P. Severe rhabdomyolysis associated with simvastatin and role of ciprofloxacin and amlodipine coadministration. Case Rep Nephrol. 2015;2015:761393.","journal-title":"Case Rep Nephrol"},{"issue":"1","key":"682_CR36","first-page":"78","volume":"16","author":"R Savant","year":"2009","unstructured":"Savant R. Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin. Can J Clin Pharmacol. 2009;16(1):78\u20139.","journal-title":"Can J Clin Pharmacol"},{"key":"682_CR37","doi-asserted-by":"crossref","unstructured":"Goldie FC, Brogan A, Boyle JG. Ciprofloxacin and statin interaction: a cautionary tale of rhabdomyolysis. BMJ Case Rep. 2016;bcr2016216048.","DOI":"10.1136\/bcr-2016-216048"},{"key":"682_CR38","unstructured":"Whitehouse Station: Merck & Co., Inc., 2015."},{"issue":"2","key":"682_CR39","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/AAC.45.2.382-392.2001","volume":"45","author":"Z Desta","year":"2001","unstructured":"Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother. 2001;45(2):382\u201392.","journal-title":"Antimicrob Agents Chemother"},{"key":"682_CR40","doi-asserted-by":"crossref","unstructured":"Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. 2011;138(7):2246\u201359.","DOI":"10.1053\/j.gastro.2010.04.001"},{"issue":"10","key":"682_CR41","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1592\/phco.27.10.1467","volume":"27","author":"KY Kim","year":"2007","unstructured":"Kim KY, Frey RJ, Epplen K, Foruhari F. Interaction between warfarin and nafcillin: case report and review of the literature. Pharmacotherapy. 2007;27(10):1467\u201370.","journal-title":"Pharmacotherapy"},{"issue":"11","key":"682_CR42","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/phar.1652","volume":"35","author":"JM Rybak","year":"2015","unstructured":"Rybak JM, Marx KR, Nishimoto AT, Rogers PD. Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. 2015;35(11):1037\u201351.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"682_CR43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ccm.2009.02.001","volume":"30","author":"GR Thompson","year":"2009","unstructured":"Thompson GR, Cadena J, Patterson TF. Overview of antifungal agents. Clin Chest Med. 2009;30(2):203\u201315.","journal-title":"Clin Chest Med"},{"issue":"1","key":"682_CR44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.mjt.0000208875.61480.c8","volume":"14","author":"P Stang","year":"2007","unstructured":"Stang P, Morris L, Kempf J, Henderson S, Yood MU, Oliveria S. The coprescription of contraindicated drugs with statins: continuing potential for increased risk of adverse events. Am J Ther. 2007;14(1):30\u201340.","journal-title":"Am J Ther"},{"issue":"3","key":"682_CR45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s002280000127","volume":"56","author":"T Kantola","year":"2000","unstructured":"Kantola T, Backman JT, Niemi M, Kivist\u00f6 KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol. 2000;56(3):225\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"682_CR46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00228-002-0508-8","volume":"58","author":"KJ Cooper","year":"2002","unstructured":"Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 2002;58(8):527\u201331.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"682_CR47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2125.1998.00034.x","volume":"46","author":"KT Kivisto","year":"2002","unstructured":"Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol. 2002;46(1):49\u201353.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"682_CR48","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0009-9236(96)90167-8","volume":"60","author":"PJ Neuvonen","year":"1996","unstructured":"Neuvonen PJ, Jalava K-M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1996;60(1):54\u201361.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"682_CR49","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(98)90165-5","volume":"63","author":"PJ Neuvonen","year":"1998","unstructured":"Neuvonen PJ, Kantola T, Kivist KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998;63(3):332\u201341.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"682_CR50","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/cpdd.280","volume":"6","author":"T Yamazaki","year":"2017","unstructured":"Yamazaki T, Desai A, Goldwater R, Han D, Lasseter KC, Howieson C, et al. Pharmacokinetic interactions between isavuconazole and the drug transporter substrates atorvastatin, digoxin, metformin, and methotrexate in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(1):66\u201375.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"682_CR51","unstructured":"Oravig [package insert]. Schorndorf: Midatech Pharma US Inc.; 2015."},{"issue":"2","key":"682_CR52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","volume":"38","author":"K Venkatakrishnan","year":"2000","unstructured":"Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism. Clin Pharmacokinet. 2000;38(2):111\u201380.","journal-title":"Clin Pharmacokinet"},{"key":"682_CR53","unstructured":"Vfend [package isnert]. New York: Pfizer; 2015."},{"issue":"3","key":"682_CR54","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1345\/aph.1C261","volume":"37","author":"MM Pearson","year":"2003","unstructured":"Pearson MM, Rogers PD, Cleary JD, Chapman SW. Voriconazole: a new triazole antifungal agent. Ann Pharmacother. 2003;37(3):420\u201332.","journal-title":"Ann Pharmacother"},{"issue":"13","key":"682_CR55","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2146\/ajhp130527","volume":"71","author":"SD Burdette","year":"2014","unstructured":"Burdette SD, Oleson F, McDaneld PM, Benziger D, Patel HN. Dosing strategy to allow continued therapy with daptomycin after asymptomatic increases in creatine kinase levels. Am J Health Syst Pharm. 2014;71(13):1101\u20137.","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"682_CR56","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/1060028013514377","volume":"48","author":"ML Berg","year":"2014","unstructured":"Berg ML, Estes LL, Dierkhising RA, Curran B, Enzler MJ. Evaluation of impact of statin use on development of CPK elevation during daptomycin therapy. Ann Pharmacother. 2014;48(3):320\u20137.","journal-title":"Ann Pharmacother"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-017-0682-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-017-0682-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-017-0682-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T21:51:37Z","timestamp":1750888297000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-017-0682-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,9]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1007\/s11883-017-0682-x","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,9]]},"article-number":"46"}}